{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:08:29Z","timestamp":1780499309977,"version":"3.54.1"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Primary aldosteronism (PA) is a common cause of hypertension. It entails elevated morbidity and mortality that do not sufficiently improve with conventional antihypertensive therapy. Screening for PA by plasma aldosterone\u2013renin ratio (ARR) enables discovery and specific treatment of affected patients. By screening primary care patients with hypertension and evaluating them further according to the Endocrine Society guidelines, we aimed to assess the prevalence of PA, the factors affecting biochemical diagnostics, and the outcome of lateralization studies and of specific treatment of the discovered PA cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, patients, and methods<\/jats:title><jats:p>Prospective evaluation of screening for PA was conducted in 1,181 patients. Screening by ARR was performed under current therapy, but without mineralocorticoid receptor antagonists (MRA), under normokalemia, and confirmed by the intravenous saline suppression test, SST#1. Those with results in a defined gray zone underwent therapy adjustment and then completed SST#2. Plasma aldosterone and ARR were compared under different stages of the diagnostic process. All patients with PA were offered adrenal venous sampling, or, in certain cases, adrenocortical-specific positron emission tomography. Lateralizing cases were offered laparoscopic adrenalectomy. Patients with bilateral disease were treated with MRA. Treatment results were assessed after a minimum of 6 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 53 discovered cases of (mostly mild) PA corresponded to its prevalence of 4.5%. Initial seated ARR was higher than recumbent ARR before SST#1. At SST#2, initial ARR and final aldosterone were higher than at SST#1. Localizing studies (accepted by 45 patients) found 14 lateralized cases. Of the 11 operated cases, 4 had aldosterone-producing adenoma, and the remainder had micro- and macronodular histopathology. A total of 31 patients had bilateral PA. Both surgical and conservative treatments were well tolerated and led to improved blood pressure and higher renin, indicating risk amelioration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>PA is prevalent among primary care patients with hypertension and can be screened for under current antihypertensive therapy. Aldosterone-producing adenoma was rare in this cohort. The study results support active screening of primary care patients with hypertension for PA in order to offer appropriate treatment options.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1555572","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T04:10:21Z","timestamp":1744603821000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Screening for primary aldosteronism in 1,181 Swedish primary care patients with hypertension"],"prefix":"10.3389","volume":"16","author":[{"given":"Nikita","family":"Makhnov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"\u00c5kerstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Axling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Andernord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Bergenheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauritz","family":"Wald\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Hellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2224898","DOI":"10.1080\/08037051.2023.2224898","article-title":"Secondary hypertension as a cause of treatment resistance","volume":"32","author":"Sudano","year":"2023","journal-title":"Blood Press"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","author":"Zhou","year":"2021","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.01.052","article-title":"Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice","volume":"69","author":"Monticone","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.07.059","article-title":"A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients","volume":"48","author":"Rossi","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-1472","article-title":"Study heterogeneity and estimation of prevalence of primary aldosteronism: A systematic review and meta-regression analysis","volume":"101","author":"K\u00e4yser","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002441","article-title":"Prevalence of primary aldosteronism and association with cardiovascular complications in patients with resistant and refractory hypertension","volume":"38","author":"Parasiliti-Caprino","year":"2020","journal-title":"J Hypertens"},{"key":"B7","doi-asserted-by":"publisher","first-page":"630","DOI":"10.7326\/M17-0882","article-title":"The spectrum of subclinical primary aldosteronism and incident hypertension: A cohort study","volume":"167","author":"Brown","year":"2017","journal-title":"Ann Intern Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: A cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.08952","article-title":"Continuum of renin-independent aldosteronism in normotension","volume":"69","author":"Baudrand","year":"2017","journal-title":"Hypertension"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00139","article-title":"The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment","volume":"39","author":"Vaidya","year":"2018","journal-title":"Endocr Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac352","article-title":"Aldosterone in chronic kidney disease and renal outcomes","volume":"43","author":"Verma","year":"2022","journal-title":"Eur Heart J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3353","article-title":"Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: A very high odds ratio for progression into arterial hypertension","volume":"98","author":"Markou","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015985","article-title":"Cardiovascular risk in primary aldosteronism: A systematic review and meta-analysis","volume":"98","author":"Wu","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpac079","article-title":"Primary aldosteronism: state-of-the-art review","volume":"35","author":"Vaidya","year":"2022","journal-title":"Am J Hypertens"},{"key":"B16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/EJE-21-0836","article-title":"Long-term mortality and cardiovascular events in patients with unilateral primary aldosteronism after targeted treatments","volume":"186","author":"Wu","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0375","article-title":"Cardiovascular outcomes and all-cause mortality in primary aldosteronism after adrenalectomy or mineralocorticoid receptor antagonist treatment: a meta-analysis","volume":"187","author":"Chen","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1210\/endrev\/bnad024","article-title":"Biomarkers to guide medical therapy in primary aldosteronism","volume":"45","author":"Hundemer","year":"2024","journal-title":"Endocr Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41591-022-02114-5","article-title":"11C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trial","volume":"29","author":"Wu","year":"2023","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1145186","article-title":"Predictive performance of aldosterone-to-renin ratio in the diagnosis of primary aldosteronism in patients with resistant hypertension","volume":"14","author":"Bioletto","year":"2023","journal-title":"Front Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/02813430600830931","article-title":"High frequency of primary hyperaldosteronism among hypertensive patients from a primary care area in Sweden","volume":"24","author":"Westerdahl","year":"2006","journal-title":"Scand J Prim Health Care"},{"key":"B24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3109\/02813432.2011.554015","article-title":"Primary aldosteronism among newly diagnosed and untreated hypertensive patients in a Swedish primary care area","volume":"29","author":"Westerdahl","year":"2011","journal-title":"Scand J Prim Health Care"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp18X694589","article-title":"Prevalence of primary aldosteronism in primary care: a cross-sectional study","volume":"68","author":"K\u00e4yser","year":"2018","journal-title":"Br J Gen Pract"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1055\/a-1938-4242","article-title":"Prevalence of primary aldosteronism in newly diagnosed hypertensive patients in primary care","volume":"130","author":"Asbach","year":"2022","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.v216.8","article-title":"Detecting primary aldosteronism in Australian primary care: a prospective study","volume":"216","author":"Libianto","year":"2022","journal-title":"Med J Aust"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvac002","article-title":"International multicenter survey on screening and confirmatory testing in primary aldosteronism","volume":"188","author":"Naruse","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ21-0508","article-title":"Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021","volume":"69","author":"Naruse","year":"2022","journal-title":"Endocr J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1210\/clinem\/dgaa484","article-title":"International histopathology consensus for unilateral primary aldosteronism","volume":"106","author":"Williams","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14958","article-title":"Immunohistochemical staining seems mandatory for individualizing and shortening follow-up in unilateral primary aldosteronism","volume":"99","author":"Gunnarsdottir","year":"2023","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.121.17348","article-title":"Single-center prospective cohort study on the histopathology, genotype, and postsurgical outcomes of patients with primary aldosteronism","volume":"78","author":"Meyer","year":"2021","journal-title":"Hypertension"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0123","article-title":"True unilateral primary aldosteronism exists, and unilateral adrenalectomy saves lives","volume":"186","author":"Reincke","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2273","article-title":"11 C]Metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings","volume":"91","author":"Hennings","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s00259-022-05957-9","article-title":"First-in-human evaluation of [18F]CETO: a novel tracer for adrenocortical tumours","volume":"50","author":"Silins","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1537","article-title":"Evaluation of the sensitivity and specificity of 11 C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by conn\u2019s adenomas","volume":"97","author":"Burton","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30135-3","article-title":"Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort","volume":"5","author":"Williams","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2012.08.042","article-title":"Unilateral adrenal hyperplasia: A novel cause of surgically correctable primary hyperaldosteronism","volume":"152","author":"Iacobone","year":"2012","journal-title":"Surgery"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3283656b54","article-title":"Test characteristics of the aldosterone-to-renin ratio as a screening test for primary aldosteronism","volume":"32","author":"Jansen","year":"2014","journal-title":"J Hypertens"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.16429","article-title":"Intraindividual variability of aldosterone concentrations in primary aldosteronism: implications for case detection","volume":"77","author":"Yozamp","year":"2021","journal-title":"Hypertension"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa703","article-title":"Aldosterone is aberrantly regulated by various stimuli in a high proportion of patients with primary aldosteronism","volume":"106","author":"St-Jean","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.13772","article-title":"Renin-angiotensin-aldosterone system triple-A analysis for the screening of primary aldosteronism","volume":"75","author":"Burrello","year":"2020","journal-title":"Hypertension"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2021.03.005","article-title":"Primary aldosteronism","volume":"32","author":"Funder","year":"2022","journal-title":"Trends Cardiovasc Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03520-6","article-title":"Screening for primary aldosteronism on and off interfering medications","volume":"83","author":"Li","year":"2023","journal-title":"Endocrine"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae094","article-title":"Performance of aldosterone-to-renin ratio before washout of antihypertensive drugs in screening of primary aldosteronism","volume":"109","author":"Liu","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-024-03798-0","article-title":"Feasibility of primary aldosteronism diagnosis in initial evaluation without medication withdrawal or confirmatory tests","volume":"85","author":"Ruiz-S\u00e1nchez","year":"2024","journal-title":"Endocrine"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12831","article-title":"Diagnosis and treatment of primary aldosteronism: practical clinical perspectives","volume":"285","author":"Young","year":"2019","journal-title":"J Intern Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ11-0133","article-title":"Guidelines for the diagnosis and treatment of primary aldosteronism -The Japan Endocrine Society 2009-","volume":"58","author":"Nishikawa","year":"2011","journal-title":"Endocr J"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.02.041","article-title":"The time has come for systematic screening for primary aldosteronism in all hypertensives \u2217","volume":"69","author":"Maiolino","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2004.041780","article-title":"Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity","volume":"51","author":"Schwartz","year":"2005","journal-title":"Clin Chem"},{"key":"B51","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1055\/a-0672-0836","article-title":"Aldosterone to renin ratio as screening tool in primary aldosteronism","volume":"127","author":"Schilbach","year":"2019","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B52","doi-asserted-by":"publisher","first-page":"147032031665745","DOI":"10.1177\/1470320316657450","article-title":"Aldosterone\/direct renin concentration ratio as a screening test for primary aldosteronism: A meta-analysis","volume":"17","author":"Li","year":"2016","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"B53","doi-asserted-by":"publisher","first-page":"101368","DOI":"10.1016\/j.beem.2019.101368","article-title":"Primary aldosteronism: Treatment of the disease, and new therapeutic approaches","volume":"34","author":"Funder","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa606","article-title":"Evolution of the primary aldosteronism syndrome: updating the approach","volume":"105","author":"Vaidya","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01394","article-title":"Comparison of seated with recumbent saline suppression testing for the diagnosis of primary aldosteronism","volume":"103","author":"Stowasser","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.07214","article-title":"Suppression of aldosterone secretion after recumbent saline infusion does not exclude lateralized primary aldosteronism","volume":"68","author":"Cornu","year":"2016","journal-title":"Hypertension"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1053\/meta.2002.30498","article-title":"Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selective adrenal venous sampling","volume":"51","author":"Omura","year":"2002","journal-title":"Metabolism"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-005-0594-8","article-title":"Primary hyperaldosteronism secondary to unilateral adrenal hyperplasia: an unusual cause of surgically correctable hypertension. A review of 30 cases","volume":"31","author":"Goh","year":"2007","journal-title":"World J Surg"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","article-title":"Renal outcomes in medically and surgically treated primary aldosteronism","volume":"72","author":"Hundemer","year":"2018","journal-title":"Hypertension"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.2003","article-title":"Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism","volume":"3","author":"Hundemer","year":"2018","journal-title":"JAMA Cardiol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.005574","article-title":"Quantitative value of aldosterone-renin ratio for detection of aldosterone-producing adenoma: the aldosterone-renin ratio for primary aldosteronism (AQUARR) study","volume":"6","author":"Maiolino","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"B62","doi-asserted-by":"publisher","first-page":"100029","DOI":"10.1097\/01.hjh.0000745016.79540.85","article-title":"The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism","volume":"5","author":"Rossi","year":"2020","journal-title":"Int J Cardiol Hypertens"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000729","article-title":"Pathophysiology of bilateral hyperaldosteronism","volume":"29","author":"Nanba","year":"2022","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.14359","article-title":"Screening rates for primary aldosteronism in resistant hypertension: A cohort study","volume":"75","author":"Jaffe","year":"2020","journal-title":"Hypertension"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.121.18118","article-title":"Screening rates for primary aldosteronism among individuals with hypertension plus hypokalemia: A population-based retrospective cohort study","volume":"79","author":"Hundemer","year":"2022","journal-title":"Hypertension"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2023.01.447","article-title":"Underdiagnosis of primary aldosteronism: A review of screening and detection","volume":"82","author":"Funes Hernandez","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab327","article-title":"Increasing incidence of primary aldosteronism in western Sweden during 3 decades \u2013 yet an underdiagnosed disorder","volume":"106","author":"Gkaniatsa","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1153","article-title":"Seated saline suppression testing for the diagnosis of primary aldosteronism: A preliminary study","volume":"99","author":"Ahmed","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1268","article-title":"Stress-induced aldosterone hyper-secretion in a substantial subset of patients with essential hypertension","volume":"100","author":"Markou","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3551","article-title":"Diagnostic value of ACTH stimulation test in determining the subtypes of primary aldosteronism","volume":"100","author":"Jiang","year":"2015","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1555572\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T04:10:23Z","timestamp":1744603823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1555572\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":70,"alternative-id":["10.3389\/fendo.2025.1555572"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1555572","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"article-number":"1555572"}}